The Brigham and Women's Hospital, Inc.

Bin Ye

Daniel Cramer

Samuel C Mok

Steven Skates

Ross S Berkowitz

The present invention is directed to diagnostic methods based upon the detection of peptides derived from the degradation of CA125. In particular, it is concerned with assays of urine samples collected from women for the purpose of determining whether they are at increased risk for having ovarian cancer, have decreased their risk as the result of clinical or non-clinical procedures, to monitor the efficacy of a treatment method, or to determine whether cancer has recurred or advanced.

Urinary CA125 peptides as biomarkers of ovarian cancer

The present invention is directed to methods of identifying women at increased risk of having ovarian cancer. Identification is based upon the extent to which biological samples derived from the women exhibit elevated levels of eosinophil-derived neurotoxin (EDN).

Eosinophil-derived neurotoxin as a marker for ovarian cancer

The present invention is directed to a method for determining whether a woman has, or is likely to develop, ovarian cancer based upon assays of the alpha subunit of haptoglobin.

Growing community of inventors

Brookline, MA, United States of America

Bin Ye